Zacks: Analysts Anticipate Henry Schein, Inc. (HSIC) to Announce $0.90 Earnings Per Share

Wall Street brokerages expect Henry Schein, Inc. (NASDAQ:HSIC) to report earnings per share of $0.90 for the current fiscal quarter, Zacks reports. Eight analysts have made estimates for Henry Schein’s earnings. The highest EPS estimate is $0.92 and the lowest is $0.88. Henry Schein posted earnings of $0.84 per share in the same quarter last year, which would suggest a positive year over year growth rate of 7.1%. The business is expected to report its next earnings results on Wednesday, November 1st.

On average, analysts expect that Henry Schein will report full-year earnings of $3.64 per share for the current year, with EPS estimates ranging from $3.62 to $3.71. For the next financial year, analysts forecast that the company will report earnings of $4.02 per share, with EPS estimates ranging from $3.95 to $4.10. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Henry Schein.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.88 earnings per share for the quarter, beating analysts’ consensus estimates of $0.86 by $0.02. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The firm had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period last year, the firm posted $0.82 EPS. Henry Schein’s quarterly revenue was up 6.4% on a year-over-year basis.

HSIC has been the subject of several analyst reports. Stifel Nicolaus restated a “hold” rating on shares of Henry Schein in a research report on Thursday, July 6th. Credit Suisse Group reiterated a “hold” rating and issued a $80.00 price objective on shares of Henry Schein in a research report on Thursday, July 13th. Jefferies Group LLC reiterated a “hold” rating and issued a $88.50 price objective on shares of Henry Schein in a research report on Friday, July 21st. BidaskClub downgraded Henry Schein from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, Northcoast Research upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 price objective for the company in a research report on Monday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $92.14.

Henry Schein (HSIC) traded up 0.66% during trading on Tuesday, reaching $82.45. 1,566,149 shares of the company were exchanged. The stock has a market capitalization of $13.04 billion, a PE ratio of 24.09 and a beta of 1.09. Henry Schein has a 52-week low of $73.11 and a 52-week high of $93.50. The firm’s 50 day moving average is $82.72 and its 200 day moving average is $87.37.

Henry Schein declared that its board has authorized a share repurchase plan on Monday, September 18th that allows the company to repurchase $400.00 million in shares. This repurchase authorization allows the company to purchase up to 6.3% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its shares are undervalued.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/10/27/zacks-analysts-anticipate-henry-schein-inc-hsic-to-announce-0-90-earnings-per-share.html.

In related news, SVP Paul Rose sold 2,126 shares of Henry Schein stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $172.51, for a total value of $366,756.26. Following the completion of the transaction, the senior vice president now directly owns 17,841 shares in the company, valued at approximately $3,077,750.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.19% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Pensionfund Sabic grew its stake in Henry Schein by 100.0% in the 3rd quarter. Pensionfund Sabic now owns 18,800 shares of the company’s stock valued at $1,541,000 after buying an additional 9,400 shares in the last quarter. Pensionfund DSM Netherlands grew its stake in Henry Schein by 100.0% in the 3rd quarter. Pensionfund DSM Netherlands now owns 37,000 shares of the company’s stock valued at $3,034,000 after buying an additional 18,500 shares in the last quarter. Neville Rodie & Shaw Inc. grew its stake in Henry Schein by 102.2% in the 3rd quarter. Neville Rodie & Shaw Inc. now owns 121,119 shares of the company’s stock valued at $9,931,000 after buying an additional 61,227 shares in the last quarter. Gs Investments Inc. purchased a new position in Henry Schein in the 2nd quarter valued at approximately $884,000. Finally, Toronto Dominion Bank grew its stake in Henry Schein by 25.7% in the 2nd quarter. Toronto Dominion Bank now owns 26,872 shares of the company’s stock valued at $4,917,000 after buying an additional 5,487 shares in the last quarter. Institutional investors and hedge funds own 44.74% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply